KRAS is the single most commonly altered gene in pancreatic cancer. A change (mutation) in the KRAS gene is found in roughly 90 percent of pancreatic ductal adenocarcinomas, the most common type of pancreatic cancer, meaning that for most patients, a KRAS mutation is part of what drives the tumor. A “biomarker” is a measurable …
Read More »
If your pathology report or molecular test results mention a RAS mutation — most commonly NRAS, HRAS, or KRAS — this refers to a change in one of three closely related genes that help control how thyroid cells grow and divide. RAS mutations are among the most common molecular findings in thyroid cancer and in …
Read More »
KRAS and NRAS are two of the most commonly tested genes in colorectal cancer. When either gene carries a mutation — a change that causes it to malfunction — the result has direct consequences for your treatment plan. Most importantly, KRAS and NRAS mutations predict that a class of targeted drugs called anti-EGFR therapy will …
Read More »
KRAS is one of the most commonly mutated genes in human cancer. In the lung, mutations in the KRAS gene are found in approximately 25–30% of non-small cell lung cancers, making it the single most frequently altered driver gene in this disease, more common than EGFR mutations or ALK rearrangements. KRAS encodes a protein that …
Read More »
KRAS is a gene found in nearly all cells in the body. Genes are instructions made of DNA that tell cells how to grow, divide, and function. The KRAS gene provides instructions for making a protein that helps control how cells respond to growth signals. KRAS is also considered a biomarker. A biomarker is a …
Read More »
